Archives: Agenda

• Identifying key markets for global expansion – how to analyse global trends to determine expansion opportunities
• Navigating regulations and compliance in different regions – import/export laws, labelling regulations and tax structures in different markets
• Maintaining brand consistency internationally – how to build a culturally relevant brand for international customers

• How RTD cocktails are reshaping consumer habits
• Packaging innovations driving market success

Seedlip founder and game changer Ben Branson, takes on 10 quick fire questions from Jonathan Ford, co-founder of Pearlfisher and Rosalind Michaluk, Strategy Director at Pearlfisher — the creative force behind Seedlip’s iconic branding — to uncover what the past 10 years tells us about the next.

• Nootropics are the New Buzz: How brain-boosting ingredients are creating a white space for brands, and what makes nootropics different from other functional claims
• Bridging Science & Storytelling: Practical ways to educate consumers on complex ingredients without losing the ritual and fun of the drinking occasion
• From Ingredient to Icon: What it takes for a mind-enhancing beverage to stand out. Formulation, sourcing, regulatory guardrails, and flavour are all part of the brand promise
• Lessons from Kin: How we’ve navigated brand development, marketing, and community-building around cognitive function
• A Wellness Status Symbol: Why the next generation of drinkers sees cognitive wellness as the ultimate luxury, and how that shifts category strategy for innovators and suppliers alike
• Where We Go Next: What’s on the horizon for brands ready to push beyond mindful drinking into mind-bending territory

• Dives into GLP-1s and how this is changing beverage consumption
• It explores how GLP-1s are driving a shift from alcohol to soft drinks and how this impacts innovation
• Unpacks what innovation needs to look like for GLP-1 consumers – touching on hydration, greater functionality, taste innovation to deliver on consumer experiences

• How pharma can move digital health and digital diagnostics from pilots to scalable real-world solutions
• Key building blocks for adoption, including data, clinical evidence, technology development, and clinical workflow integration
• Practical lessons from real programs across screening, monitoring, and patient-centric digital tools

• Why tissue biopsies are sometimes essential in clinical trials for novel therapeutics
• Question-based framework to align tissue collection and analysis with clinical trial objectives and timelines
• Emerging biomarker technologies including digital pathology, artificial intelligence, and multiplex spatial biology